CompoAtlas

Ivizon Max 2.0 for Diabetic Retinopathy

Natural health product licensed in Canada

If this product were sold in France

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Vitamine C

Source : Acide ascorbique

125 milligramme500,000 µg
Vitamine E

Source : Succinate d'acide de d-alpha tocophéryle

67 mg ATNot calculated
Zinc

Source : Picolinate de zinc

5 milligramme20,000 µg
Chrome

Source : Picolinate de chrome (III)

125 microgrammesNot calculated
Cuivre

Source : Diglycinate de cuivre (II)

0.5 milligramme2,000 µg
Sélénium

Source : Sélénométhionine

12.5 microgrammesNot calculated
Lutéine

Source : Lutéine

2.5 milligrammeNot calculated
(3R,3'R)-bêta,bêta-Carotène-3,3'-diol

Source : Zeaxanthin

0.5 milligrammeNot calculated
(3R,3'S)-b,b-Carotene-3,3'-diol

Source : Meso-Zeaxanthin

2.5 milligrammeNot calculated
Vaccinium myrtillus

Source : Fruit

Extract : Matériel brut sec

Extraction ratio : 100:1

Dry plant equivalent : 3,000 milligramme

Potency : 10.8 milligramme Anthocyanidins

30 milligrammeNot calculated
Pinus pinaster

Source : Écorce (tige)

Extract : Matériel brut sec

Extraction ratio : 4:1

Dry plant equivalent : 150 milligramme

Potency : 28.125 milligramme Procyanidins

37.5 milligrammeNot calculated
Thiamine

Source : Benfotiamine

25 milligramme100,000 µg
3,3',4',5,7-Pentahydroxyflavone-3-rutinoside

Source : Rutine

6.25 milligrammeNot calculated

Non-medicinal ingredients

Hypromellose, Stéarate de magnésium

PopulationAgeQuantity per servingFrequency
AdultesNot specified2 Capsule2 Tous les jours

Uses authorised in Canada

Text supplied in English because no French text is available.

Antioxidant for the maintenance of eye health. Used in Herbal Medicine to help slow the progression of disorders of the eye, such as diabetic and hypertensive retinopathy, and macular degeneration. Provides support for healthy glucose metabolism.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

No French warning text available in the imported data.

Warnings are available in English on the official record.

Product record

Licence holder
2201371 Ontario Inc.
NPN or DIN-HM
80073843
Status
Inactive licence
Licence date
17 November 2016
Revision date
Not provided
Form
Capsule
Route of administration
Orale
Application type
Non traditionnelle

Source

Official Health Canada record, licence 80073843

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Vaccinium myrtillus
    Read the warning, when it applies and the studies cited

    BILBERRY - VACCINIUM MYRTILLUS - Buccal

    Route of administration: Buccal (Blumenthal et al. 2000)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 30 January 2026

    BILBERRY - VACCINIUM MYRTILLUS - Oral

    Route of administration: Oral (Blumenthal et al. 2000)

    Cautions and warnings

    Condition of application: Relief of diarrhea.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: Slowing the progression of disorders of the eye and to relieve symptoms related to non-complicated CVI.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

    Health Canada monograph dated 25 October 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Ivizon Max 2.0 for Diabetic Retinopathy”, https://compoatlas.com/en/supplements/canada/80073843-ivizon-max-2-0-for-diabetic-retinopathy, updated 17 November 2016.

Enter to analyse, Shift+Enter for a new line